FIRE-4 Anti-EGFR rechallenge with cetuximab in the third line in mCRC with RAS wild type
This Medudy course is a video tutorial for physicians on the topic of "FIRE-4: Anti-EGFR rechallenge with cetuximab in the third line of treatment for mCRC with RAS wild type." The study focuses on the strategic and optimal use of anti-EGFR therapy with cetuximab in metastatic colorectal cancer (mCRC) with RAS wild type across different lines of treatment. Part of the study dealt with [...]